The antithrombotic activity of EP224283, a neutralizable dual factor Xa inhibitor/glycoprotein IIbIIIa antagonist, exceeds that of the coadministered parent compounds

Journal of Pharmacology and Experimental Therapeutics

Volumn 338, Issue 2, 2011, Pages 412-420

  Hechler, Béatrice ^a   Freund, Monique ^a   Alame, Ghina ^a,b   Leguay, Cécile ^a   Gaertner, Sébastien ^a   Cazenave, Jean Pierre ^a   Petitou, Maurice ^b   Gachet, Christian ^a  

^a UNIVERSITÉ DE STRASBOURG   (France)

^b Endotis Pharma   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ANTITHROMBIN; APOLIPOPROTEIN E; AVIDIN; BLOOD CLOTTING FACTOR 10A INHIBITOR; EP 224283; FERRIC CHLORIDE; FIBRINOGEN RECEPTOR; FIBRINOGEN RECEPTOR ANTAGONIST; IDRAPARINUX; IDRAPARINUX PLUS TIROFIBAN; THROMBIN; TIROFIBAN; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBODY LABELING; ANTICOAGULATION; ARTICLE; ATHEROSCLEROTIC PLAQUE; BLEEDING TIME; BLOOD VESSEL OCCLUSION; CAROTID ARTERY THROMBOSIS; CONTINUOUS INFUSION; CONTROLLED STUDY; DISEASE MODEL; DRUG DOSE COMPARISON; DRUG STRUCTURE; IN VIVO STUDY; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; RECEPTOR BINDING; THROMBOCYTE AGGREGATION INHIBITION; THROMBOEMBOLISM;

ANIMALS; BIOTIN; DISEASE MODELS, ANIMAL; DRUG COMBINATIONS; FACTOR XA; FIBRINOLYTIC AGENTS; HUMANS; MALE; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; OLIGOSACCHARIDES; PLATELET AGGREGATION INHIBITORS; PLATELET GLYCOPROTEIN GPIIB-IIIA COMPLEX; RATS; THROMBOEMBOLISM; TYROSINE;

EID: 79960571410     PISSN: 00223565     EISSN: 15210103     Source Type: Journal    
DOI: 10.1124/jpet.111.181321     Document Type: Article

References (30)

1. Angiolillo DJ, Bhatt DL, Gurbel PA, and Jennings LK (2009) Advances in antiplatelet therapy: agents in clinical development. Am J Cardiol 103:40A-51A.
2. Barrett JS, Murphy G, Peerlinck K, De Lepeleire I, Gould RJ, Panebianco D, Hand E, Deckmyn H, Vermylen J, and Arnout J (1994) Pharmacokinetics and pharmacodynamics of MK-383, a selective non-peptide platelet glycoprotein-IIb/IIIa receptor antagonist, in healthy men. Clin Pharmacol Ther 56:377-388. (Pubitemid 24339084)
3. Bhatt DL (2009) Prasugrel in clinical practice. N Engl J Med 361:940-942.
4. Blick SK, Orman JS, Wagstaff AJ, and Scott LJ (2008) Fondaparinux sodium: a review of its use in the management of acute coronary syndromes. Am J Cardiovasc Drugs 8:113-125.
5. Bonaca MP, Steg PG, Feldman LJ, Canales JF, Ferguson JJ, Wallentin L, Califf RM, Harrington RA, and Giugliano RP (2009) Antithrombotics in acute coronary syndromes. J Am Coll Cardiol 54:969-984.
6. Cazenave JP, Ohlmann P, Cassel D, Eckly A, Hechler B, and Gachet C (2004) Preparation of washed platelet suspensions from human and rodent blood. Methods Mol Biol 272:13-28.
7. Day SM, Reeve JL, Myers DD, and Fay WP (2004) Murine thrombosis models. Thromb Haemost 92:486-494. (Pubitemid 39248005)
8. Díez JG and Cohen M (2009) Balancing myocardial ischemic and bleeding risks in patients with non-ST-segment elevation myocardial infarction. Am J Cardiol 103:1396-1402.
9. DiMinno G and Silver MJ (1983) Mouse antithrombotic assay: a simple method for the evaluation of antithrombotic agents in vivo. Potentiation of antithrombotic activity by ethyl alcohol. J Pharmacol Exp Ther 225:57-60. (Pubitemid 13137003)
10. Eckly A, Hechler B, Freund M, Zerr M, Cazenave JP, Lanza F, Mangin PH, and Gachet C (2011) Mechanisms underlying FeCl3-induced arterial thrombosis. J Thromb Haemost 9:779-789.
11. Harenberg J (2009) Development of idraparinux and idrabiotaparinux for anticoagulant therapy. Thromb Haemost 102:811-815.
12. Hechler B and Gachet C (2011) Comparison of two murine models of thrombosis induced by atherosclerotic plaque injury. Thromb Haemost doi:10.1160/THS10-11-0730.
13. Hechler B, Nonne C, Roh EJ, Cattaneo M, Cazenave JP, Lanza F, Jacobson KA, and Gachet C (2006) MRS2500 [2-iodo-N6-methyl-(N)-methanocarba-2′- deoxyadenosine-3′,5′-bisphosphate], a potent, selective, and stable antagonist of the platelet P2Y1 receptor with strong antithrombotic activity in mice. J Pharmacol Exp Ther 316:556-563. (Pubitemid 43130981)
14. Herbert JM, Hérault JP, Bernat A, van Amsterdam RG, Lormeau JC, Petitou M, van Boeckel C, Hoffmann P, and Meuleman DG (1998) Biochemical and pharmacological properties of SANORG 34006, a potent and long-acting synthetic pentasaccharide. Blood 91:4197-4205. (Pubitemid 28261983)
15. Kurz KD, Main BW, and Sandusky GE (1990) Rat model of arterial thrombosis induced by ferric chloride. Thromb Res 60:269-280.
16. Kushner FG, Hand M, Smith SC Jr, King SB 3rd, Anderson JL, Antman EM, Bailey SR, Bates ER, Blankenship JC, Casey DE Jr, et al. (2009) 2009 focused updates: ACC/AHA guidelines for the management of patients with ST-elevation myocardial infarction (updating the 2004 guideline and 2007 focused update) and A CC/AHA/SCAI guidelines on percutaneous coronary intervention (updating the 2005 guideline and 2007 focused update) a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol 54:2205-2241.
17. Léon C, Eckly A, Hechler B, Aleil B, Freund M, Ravanat C, Jourdain M, Nonne C, Weber J, Tiedt R, et al. (2007) Megakaryocyte-restricted MYH9 inactivation dramatically affects hemostasis while preserving platelet aggregation and secretion. Blood 110:3183-3191. (Pubitemid 350106310)
18. Léon C, Freund M, Ravanat C, Baurand A, Cazenave JP, and Gachet C (2001) Key role of the P2Y(1) receptor in tissue factor-induced thrombin-dependent acute thromboembolism: studies in P2Y(1)-knockout mice and mice treated with a P2Y(1) antagonist. Circulation 103:718-723.
19. Léon C, Hechler B, Freund M, Eckly A, Vial C, Ohlmann P, Dierich A, LeMeur M, Cazenave JP, and Gachet C (1999) Defective platelet aggregation and increased resistance to thrombosis in purinergic P2Y(1) receptor-null mice. J Clin Invest 104:1731-1737. (Pubitemid 30053190)
20. Libby P (2008) The molecular mechanisms of the thrombotic complications of atherosclerosis. J Intern Med 263:517-527.
21. Mackman N (2008) Triggers, targets and treatments for thrombosis. Nature 451:914-918.
22. Michelson AD (2010) Antiplatelet therapies for the treatment of cardiovascular disease. Nat Rev Drug Discov 9:154-169.
23. Patrono C, Baigent C, Hirsh J, Roth G, and American College of Chest Physicians (2008) Antiplatelet drugs: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest 133:199S-233S.
24. Perrault C, Mangin P, Santer M, Baas MJ, Moog S, Cranmer SL, Pikovski I, Williamson D, Jackson SP, Cazenave JP, et al. (2003) Role of the intracellular domains of GPIb in controlling the adhesive properties of the platelet GPIb/V/IX complex. Blood 101:3477-3484. (Pubitemid 36857930)
25. Petitou M and van Boeckel CA (2004) A synthetic antithrombin III binding pentasaccharide is now a drug! What comes next? Angew Chem Int Ed Engl 43:3118-3133.
26. Prandoni P, Tormene D, Perlati M, Brandolin B, and Spiezia L (2008) Idraparinux: review of its clinical efficacy and safety for prevention and treatment of thromboembolic disorders. Expert Opin Investig Drugs 17:773-777. (Pubitemid 351843619)
27. Sakhuja R, Yeh RW, and Bhatt DL (2010) Antiplatelet agents in acute coronary syndromes. Curr Probl Cardiol 35:123-170.
28. Savi P, Herault JP, Duchaussoy P, Millet L, Schaeffer P, Petitou M, Bono F, and Herbert JM (2008) Reversible biotinylated oligosaccharides: a new approach for a better management of anticoagulant therapy. J Thromb Haemost 6:1697-1706.
29. Schulman S and Spencer FA (2010) Antithrombotic drugs in coronary artery disease: risk benefit ratio and bleeding. J Thromb Haemost 8:641-650.
30. Westrick RJ, Winn ME, and Eitzman DT (2007) Murine models of vascular thrombosis (Eitzman series). Arterioscler Thromb Vasc Biol 27:2079-2093. (Pubitemid 350287234)